Document:

Filed by Bowne Pure Compliance

Exhibit 10.28

CONSULTING AGREEMENT

This CONSULTING AGREEMENT (the “Agreement”) is hereby entered into by and between Dr. J.
Claude Bennett (“Consultant”) and BioCryst Pharmaceuticals, Inc., a Delaware Corporation, 2190
Parkway Lake Drive, Birmingham, Alabama 35244 (“BioCryst”), and shall be effective as of June 13,
2008 (the “Effective Date”).

W I T N E S S E T H:

In consideration of the services rendered by Consultant to BioCryst, the compensation to be
paid to Consultant by BioCryst, and the mutual promises and agreements hereinafter set forth, the
parties hereto agree as follows:

	1.	 	Term. This Agreement will commence on the Effective Date, and continue in effect for
five (5) years, (the “Term”) unless terminated earlier pursuant to Section 10 of this
Agreement.
	 
	2.	 	Services. Consultant agrees to render the requested services (“Services”) to
BioCryst for the term of this Agreement. The Services shall include, but are not limited to,
those set forth in Exhibit A hereto and the provision to BioCryst of Consultant’s knowledge,
experience, skill and judgment in the areas set forth on Exhibit A. Consultant also agrees
to submit to BioCryst, in a timely manner, any and all Results of Consultant’s work under this
Agreement. The term “Results” means the work product resulting from Consultant’s performance
of Services under this Agreement and, includes, without limitation, all deliverables described
in Exhibit A and all “Developments” (as defined in Section 5 below) and all documentation of
work performed under this Agreement. Consultant agrees to keep complete, accurate and
authentic accounts, notes, data and records of all Results and Developments made by Consultant
in the course of this Agreement, and in the manner and form requested by BioCryst. Consultant
shall not utilize any third party in the performance of the Services without the prior written
consent of BioCryst.

	 
	 	 	The Services rendered under this Agreement constitute services in accordance with the terms of
the BioCryst Stock Incentive Plan (“the Plan”) and therefore Consultant’s stock options
received while in the employment of BioCryst will continue to vest during the term of this
Agreement in accordance with the provisions of the Plan. Without limiting the foregoing, the
parties agree that there has not been and will not be any lapse of “Services” rendered to
BioCryst with respect to the transition of Consultant from an Employee of BioCryst immediately
prior to the effectiveness of this Agreement to a consultant or independent contractor pursuant
to this Agreement, and the existing, outstanding stock options heretofore granted to Dr. J.
Claude Bennett shall remain in full force and effect, notwithstanding the transition of
Consultant from Employee status to Consultant or independent contractor status. As a condition
precedent to this Agreement the Audit Committee of the Board of Directors of BioCryst shall
authorize and approve this Consulting Agreement. It is contemplated that Consultant will tender
his resignation as an officer and director of BioCryst, effective June 13, 2008, upon the due
approval by the Audit Committee of the Board of Directors, and this Agreement shall become
effective on June 13, 2008, simultaneously with effectiveness of such resignations as officer
and director.

 

 

 

	3.	 	Payment and Expenses. During this term of Agreement, Consultant shall be paid a
fee of Three Thousand Dollars ($3,000) per month for the Services under this Agreement and as
described in Exhibit A, beginning as of the Effective Date of this Agreement. In addition,
BioCryst shall reimburse Consultant for actual and reasonable out-of-pocket expenses that have
been approved by BioCryst in advance, and incurred in the performance of the Services. The
foregoing fees and expense reimbursements are Consultant’s sole compensation for rendering
Services to BioCryst. Consultant shall provide BioCryst with monthly invoices detailing
the fees and expense reimbursements that Consultant believes are due under this Agreement,
and shall itemize and provide receipts for all expenses. BioCryst agrees to pay approved
invoices within thirty (30) days of receipt. Consultant will not be reimbursed for individual
expenses exceeding $25.00 without a corresponding receipt. Consultant may be eligible to
receive options to purchase stock of BioCryst at the sole discretion of the Compensation
Committee. BioCryst will provide Consultant with a desk at its Birmingham offices during the
term of this Agreement. During the term of this Agreement BioCryst will permit Consultant to
keep the existing cell phone and blackberry (and will provide for replacement devices as
appropriate) and will pay the normal monthly charges for same; provided, however, in no event
will BioCryst be obligated to pay more than $250.00 per month with respect to such telephone
and Blackberry in the aggregate. Consultant shall be permitted to attend professional society
clinical/scientific meetings during the term of this Agreement and BioCryst shall reimburse
Consultant for the reasonable costs of attending such meetings; provided, that BioCryst shall
not be responsible for any amounts in excess of $10,000.00 in any calendar year.

	 
	4.	 	Proprietary Information.
	 
	 	 	a. Definition of “Proprietary Information”. Consultant understands that BioCryst
possesses and will possess Proprietary Information that is important to its business. In
addition, BioCryst frequently receives information from third parties that is confidential
in nature, and which BioCryst is obligated to keep confidential. For purposes of this
Agreement, “Proprietary Information” is all information, whether or not in writing or other
tangible form, that was or will be developed, created, or discovered by or on behalf of
BioCryst, or which became or will become known by, or was or is conveyed to BioCryst
(including, without limitation, “Results” as defined above), which has commercial value to
BioCryst or which BioCryst is obligated to keep confidential. “Proprietary Information”
includes, but is not limited to, business, financial, marketing and customer information,
product development plans, forecasts, inventions (whether patentable or not) technology,
know-how, processes, data, ideas, techniques, inventions, trade secrets, chemical materials,
biological materials, genetic sequences, data, technical information, information about
software programs and subroutines, source and object code, databases, database criteria,
processes, designs, methodologies, internal documentation, works of authorship, the salaries
and terms of compensation of other individuals, client and supplier lists, contacts at or
knowledge of clients or prospective clients of BioCryst, and other information concerning
the actual or anticipated products or services, business, research or
development, or any information which is received in confidence by or for BioCryst
from any other person.

 

2

 

	 	 	b. Definition of “BioCryst Materials”. Consultant understands that BioCryst
possesses or will possess “BioCryst Materials” which are important to its business. For
purposes of this Agreement, “BioCryst Materials” are documents or other media or tangible
items that contain or embody Proprietary Information or any other information concerning
the business, operations or plans of BioCryst or clients, whether such documents have been
prepared by Consultant or by others. “BioCryst Materials” include, but are not limited to,
blueprints, drawings, photographs, charts, graphs, notebooks, customer lists, computer
disks, tapes or printouts, sound and video recordings and other printed, typewritten or
handwritten documents, sample products, prototypes and models.

	 
	 	 	c. Ownership of Proprietary Information; Assignment. All Proprietary Information
and all title, patents, patent rights, copyrights, trade secret rights, sui generis
database rights and other intellectual or industrial property rights of any sort anywhere
in the world (collectively “Rights”) in connection therewith shall be the sole property of
BioCryst. Consultant hereby assigns to BioCryst any Rights Consultant may have or acquire
in such Proprietary Information. At all times, both during the term of this Agreement and
after its termination, Consultant will keep in confidence and trust and will not use or
disclose any Proprietary Information or anything related to it without the prior written
consent of an officer of BioCryst. Consultant acknowledges that any disclosure or
unauthorized use of Proprietary Information will constitute a material breach of this
Agreement and cause substantial harm to BioCryst for which monetary damages would not be a
fully adequate remedy and, therefore, in the event of any such breach, in addition to other
available remedies, BioCryst shall have the right to injunctive relief.

	 
	 	 	d. Ownership of BioCryst Materials. All BioCryst Materials shall be the sole
property of BioCryst. Consultant agrees that during the term of this Agreement, Consultant
will not remove any BioCryst Materials from the business premises of BioCryst or deliver
any BioCryst Materials to any person or entity outside BioCryst, except as required to do
in connection with performance of the Services under this Agreement. Consultant further
agrees that, immediately upon BioCryst’s request and in any event upon completion of the
Services or termination of this Agreement, Consultant shall deliver within fifteen (15)
days to BioCryst all BioCryst Materials, any document or media which contains Results,
apparatus, equipment and other physical property or any reproduction of such property,
excepting only Consultant’s copy of this Agreement.

 

3

 

	5.	 	Developments.
	 
	 	 	a. Disclosure of Developments to BioCryst. Consultant will promptly disclose in
writing to BioCryst, or to any persons designated by BioCryst from time to time, all
“Developments” (which term includes, without limitation, inventions, data, chemical
materials, biological materials, works of authorship, discoveries, improvements, designs,
source and software code, trade secrets, technology,
algorithms, computer programs, audio, video or other files or other content, ideas,
processes, techniques, know-how and data, whether or not patentable), made, conceived,
reduced to practice or developed by Consultant, either alone or jointly with others, during
the term of this Agreement in connection with the Services or that relate to any
proprietary information of BioCryst. Such disclosures shall be received by BioCryst in
confidence (to the extent that they are not assigned under Section 5(b) below) and do not
extend the assignment made in Section 5(b) below.

	 
	 	 	b. Assignment of Developments. Consultant agrees that all Developments which
Consultant makes, conceives, reduces to practice or develops (in whole or in part, either
alone or jointly with others) during the term of this Agreement in connection with the
Services or which relate to any Proprietary Information shall be the sole property of
BioCryst. Consultant agrees to assign and hereby assigns to BioCryst all Rights to all
Developments. BioCryst shall be the sole owner of all Rights in connection such
Developments.

	 
	 	 	c. License. If any Rights or Developments assigned hereunder or any Results are
based on, or incorporate, or are improvements or derivatives of, or cannot be reasonably
made, used, reproduced and distributed without using or violating technology or Rights
owned or licensed by Consultant and not assigned hereunder, Consultant hereby grants
BioCryst a perpetual, worldwide, royalty- free, non-exclusive, sublicensable right and
license to exploit and exercise all such technology and Rights in support of BioCryst’s
exercise or exploitation of any Results or assigned Rights or Developments (including any
modifications, improvements and derivatives thereof).

	 
	6.	 	Right to Inspect. At all times before or after completion of the Services,
Consultant agrees to permit authorized representatives of BioCryst, upon reasonable advance
notice and during regular business hours to examine and inspect to (and where applicable make
copies of) (i) the Results and Developments and any materials relating thereto; (ii)
Consultant’s facilities used to conduct services, (iii) raw study data, (iv) and any other
relevant information necessary to confirm compliance with this Agreement and industry
guidelines. Consultant agrees to take any steps necessary to cure deficiencies in the
defined services at Consultant’s expense.

	 
	7.	 	Assistance by Consultant. Consultant agrees to perform, during and after the term of
this Agreement, all acts deemed necessary or desirable by BioCryst to permit and assist it in
evidencing, perfecting, obtaining, maintaining, defending and enforcing Rights and/or
Consultant’s assignment with respect to the Results and the Developments in any and all
countries. Such acts may include, but are not limited to, execution of documents and
assistance or cooperation in legal proceedings. Consultant hereby irrevocably designates
and appoints BioCryst and its duly authorized officers and agents, as Consultant’s agents and
attorneys-in-fact to act for and on behalf and instead of Consultant, to execute and file any
documents and to do all other lawfully permitted acts to further the above purposes with the
same legal force and effect as if executed by Consultant. BioCryst will reimburse Consultant
for all out-of-pocket expenses incurred by Consultant in connection with his performance of
this Section 7.

 

4

 

	8.	 	Non-Solicitation. Consultant will not, during the term of this Agreement, or for
one (1) year thereafter, induce or attempt to induce any person who, at the time of such
inducement, is or was, during the prior six (6) month period, an employee of BioCryst or
BioCryst’s subsidiaries, to perform work or services for any other person or entity other than
BioCryst or its subsidiaries.

	 
	9.	 	Representations and Warranties. Consultant represents and warrants that:
	 
	 	 	a. Non-disclosure of Third-party’s
Confidential Information. The performance of all
the terms of this Agreement will not breach any agreement to keep in confidence proprietary
information acquired by Consultant in confidence or in trust prior to the execution of this
Agreement, and Consultant has not entered into, and Consultant agrees not to enter into,
any agreement, either written or oral, that conflicts or might conflict with Consultant’s
performance of the Services and other obligations under this Agreement;

	 
	 	 	b. Debarment. Consultant shall comply with all applicable laws and regulations
related to the performance of the Services; Consultant has not been, and shall not be
debarred by the FDA under 21 USC 335a and/or disqualified under 21
CFR 312.70; Consultant has not and shall not utilize any individual or facility that has been
so disqualified or debarred in the performance of the Services; Consultant shall
immediately notify BioCryst upon its learning of any person or entity providing services in
any capacity in connection with this agreement that is or becomes so debarred or
disqualified or receives notice of an action of or for disbarment or
disqualification.

	 
	10.	 	Termination. This Agreement may be terminated by either BioCryst or the Consultant at
any time, for any reason, with or without cause, by giving thirty (30) days prior written
notice to the other party. Upon receipt of notice of termination, the receiving party shall
cease performing services, unless otherwise notified. Termination of this Agreement under the
provision of this section 10 shall not release either party from any obligation and payment
becoming due prior to the effective date of termination, if such termination is not caused by
the default of either party. In the event of termination of this Agreement as a result of (i)
the expiration of the stated Term of this Agreement, (ii) early termination by the Consultant,
(iii) the Consultant’s death, or (iv) by BioCryst for Cause, then Consultant shall receive
fees accrued and expenses earned though the effective termination date and shall not be
entitled to fees or expenses subsequent to that date.

	 
	 	 	For purposes of this Agreement, a termination for “Cause” shall mean a determination by BioCryst
that this Agreement should be terminated for any of the following reasons: (i) the failure or
refusal to comply in any material respect with lawful policies, standards or regulations of
BioCryst; (ii) a violation of a federal or state law or regulation applicable to the business of
BioCryst; (iii) conviction or plea of no contest to a felony under the laws of the United States
or any State; (iv) fraud or misappropriation of property belonging to BioCryst or its affiliates;
(v) a breach in any material respect of the terms of any confidentiality, invention assignment or
proprietary
information agreement with BioCryst or client, or (vi) misconduct or gross negligence in
connection with the Services.

 

5

 

	 	 	If BioCryst terminates this Agreement without Cause prior to end of its Term, or if during the
Term of this Agreement there is a Change of Control (as defined below) at BioCryst, then all
equity awards granted to Consultant, either as an Employee prior to this Agreement or as a
Consultant under this Agreement, prior to such termination without Cause or Change of Control,
as the case may be, shall vest in full.

	 
	 	 	“Change of Control” shall be defined as (i) a merger or consolidation in which BioCryst is not
the surviving entity, except for a transaction the principal purpose of which is to change the
State of BioCryst’s incorporation; (ii) the sale, transfer or other disposition of all or
substantially all of the assets of the company in liquidation or dissolution of BioCryst; (iii)
any reverse merger in which BioCryst is the surviving entity but in which securities possessing
more than fifty percent (50%) of the total combined voting power of BioCryst’s outstanding
securities are transferred to a person or persons different from the persons holding those
securities immediately prior to such merger; (iv) any person or related group of persons (other
than Biocryst or a person that directly or indirectly controls, is controlled by, or is under
common control with BioCryst) directly or indirectly acquires beneficial ownership (within the
meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of
the total combined voting power of BioCryst’s outstanding securities pursuant to a tender or
exchange offer made directly to BioCryst’s stockholders; or (v) a change in the composition of
the Board over a period of twenty-four (24) consecutive months or less such that a majority of
the Board members (rounded up to the next whole number) ceases, by reasons of one or more
contested elections for Board membership, to be comprised of individuals who either (A) have
been Board members continuously since the beginning of such period or (B) have been elected or
nominated for election as board members during such period by at least two-thirds of the Board
members described in Clause (A) who were still in office at the time such election nomination
was approved by the Board.

	 
	11.	 	Independent Contractor. Nothing herein contained shall be deemed to create an
agency, joint venture, partnership or franchise relationship between the parties hereto.
Consultant acknowledges that he/she is an independent contractor, is not an agent or employee
of BioCryst, is not entitled to any BioCryst employment rights or benefits and is not
authorized to act on behalf of BioCryst. Consultant shall be solely responsible for any and
all tax obligations of Consultant, including but not limited to, all city, state and federal
income taxes, social security tax and other self employment taxes incurred by Consultant, and
BioCryst shall not be responsible for withholding any such taxes from Consultant’s fee. In
addition, Consultant shall not be entitled to any employee benefits, including without
limitation, retirement, profit sharing, or medical insurance. BioCryst shall not dictate the
work hours of Consultant during the term of this Agreement. Provided that Consultant does not
divulge or use BioCryst’s Proprietary Information, Consultant shall perform the Services on a
non-exclusive basis and shall be free to accept other engagements during the term of this
Agreement. The parties hereby acknowledge and agree that BioCryst shall have no right to
control the manner, means, or method by which Consultant performs the Services. Rather,
BioCryst shall be entitled only to direct Consultant with respect to the elements of the
Services and the results to be derived by BioCryst, to inform Consultant as to where and by
when the Services shall be performed, and to review and assess the performance of the Services
by Consultant for the limited purposes of assuring that the Services have been performed and
confirming that such results were satisfactory.

 

6

 

	12.	 	Performance. The Services shall be conducted with due diligence and in full
compliance with the highest professional standards of practice in the industry. Consultant
shall comply with all applicable laws and BioCryst safety rules in the course of providing the
Services. If the Services require a license, Consultant has obtained that license and the
license is in full force and effect.

	 
	13.	 	Publicity. Consultant shall not use the name BioCryst Pharmaceuticals Inc. or any
trademarks of BioCryst in any advertising or promotional materials, without the express
written consent of BioCryst.

	 
	14.	 	Survival. Consultant agrees that all obligations under Sections 4-10, and 13-21 of
this Agreement shall continue in effect after termination of this Agreement.

	 
	15.	 	Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provisions shall be modified to the minimum extent
necessary to comply with applicable law and the intent of the parties.

	 
	16.	 	Governing Law. Consultant agrees that any dispute in the meaning, effect or validity
of this Agreement shall be resolved in accordance with the laws of the State of Alabama
without regard to the conflict of laws provisions thereof, and Consultant submits to the
exclusive jurisdiction and venue of the federal and state courts located in Jefferson County,
Alabama.

	 
	17.	 	Binding Nature; Assignment. This Agreement shall be binding upon Consultant, and
inure to the benefit of the parties hereto and their respective heirs, successors, assigns,
and personal representatives; provided, however, that Consultant shall not have that
right to assign, subcontract or otherwise transfer any of its obligations or rights under this
Agreement without first obtaining the written consent of BioCryst.

	 
	18.	 	Entire Agreement. This Agreement together with all Exhibits hereto contains the
entire understanding of the parties regarding its subject matter and supersedes all prior
negotiations, understandings and agreements between the parties, whether oral or in writing,
with respect to the subject matter hereof, and can only be modified by a subsequent written
agreement executed by the Chief Executive Officer of BioCryst.

	 
	19.	 	Notices. All notices hereunder shall be in writing and shall be delivered in person
or by registered or certified mail, return receipt requested, or sent by a nationally
recognized overnight delivery service or by confirmed facsimile to the applicable party at
its address set forth below (or at such different address as may be designated by such party
by written notice to the other party). All notices by mail shall be deemed effective upon
receipt. Notices sent by confirmed facsimile shall be deemed effective upon sending if
followed by a courtesy copy sent by overnight delivery within one day of the facsimile.

 

7

 

	 	 	 	 	 	 	 	 	 
	 	 	To BioCryst:	 	To Consultant:
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	BioCryst Pharmaceuticals, Inc.
 2190
Parkway Lake Drive
 Birmingham,
Alabama 35244
 Telephone: 205-444-4600
 Facsimile: 205-444-4640
 Attn:
Alane Barnes, General Counsel

	 	 	 	J. Claude Bennett, M.D.
 2920
Redmont Circle, #400E

Birmingham, Al 35205

205-323-0061

	20.	 	Headings. The section headings in this Agreement are for purposes of reference only.

	 
	21.	 	Facsimile and Counterparts. This Agreement may be executed via facsimile and in
counterparts, each of which shall be deemed to be an original but all of which together shall
constitute one and the same agreement.

CONSULTANT HAS READ THIS AGREEMENT CAREFULLY AND UNDERSTANDS AND ACCEPTS THE OBLIGATIONS WHICH IT
IMPOSES UPON CONSULTANT WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO
CONSULTANT TO INDUCE CONSULTANT TO SIGN THIS AGREEMENT. CONSULTANT SIGNS THIS AGREEMENT
VOLUNTARILY AND FREELY.

	 	 	 	 	 	 	 	 	 	 	 
	Dr. J. Claude Bennett	 	 	 	BioCryst Pharmaceuticals, Inc.
	 
	 	 	 	 	 	 	 	 	 	 
	Signature:

	 	/s/ J. Claude Bennett
	 	 	 	Signature:
	 	/s/ Jon P. Stonehouse	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	J. Claude Bennett
	 	 	 	Name:
	 	Jon P. Stonehouse	 	 
	Title:

	 	COO
	 	 	 	Title:
	 	President CEO	 	 

 

8

 

EXHIBIT A

SCOPE OF WORK

Consultant shall serve as advisor to the Vice President of Drug Discovery on the advancement of
Biocryst’s preclinical programs and as advisor to the VP Strategic Planning & Commercialization.
In addition, Consultant shall attend via teleconference or in person the following meetings (at
least one of each per month). Consultant’s time shall average 2 days per month during the term of
this agreement.

In connection with this Scope of Work, Consultant will be paid a consulting fee of Three
Thousand Dollars ($3000) per month beginning on the Effective Date of the Agreement plus expenses
as described in the Agreement. Consultant agrees to provide BioCryst with a Form W9 and
acknowledges that he is solely responsible for payment of all taxes on his consulting fee,
including workers’ compensation coverage.

 

9Filed by Bowne Pure Compliance

Exhibit 10.29

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	 	1. CONTRACT ID CODE	 	 	 	PAGE OF PAGES
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	1	 	 
	 
	2. AMENDMENT/MODIFICATION NO:	 	 	 	3. EFFECTIVE DATE	 	4. REQUISITION/PURC	 	5. PROJECT NO. (If applicable)
	Four (4)	 	 	 	April 4, 2008	 	N/A	 	 	 	N/A	 	 	 	 	 	 
	 
	6. ISSUED BY	 	CODE	 	 	7. ADMINISTERED
BY (If other than Item 6)	 	CODE	 
	 
	Assistant Secretary for Preparedness and Response (ASPR)

Biomedical Advanced Research and Development Authority (BARDA)

U.S. Department of Health and Human Services

330 Independence Avenue, SW Room G640

Washington, DC 20201	 	 	 	 	 	 	 	 	 	 
	 
	8. NAME AND ADDRESS OF
CONTRACTOR (No., street, county, State and ZIP Code)	 	þ 	 	9A. AMENDMENT OF SOLICITATION NO.	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	BioCryst Pharmaceuticals, Inc

2190 Parkway Lake Drive

Birmingham, AL 35244

DUNS 61-819-4609

	 	 	 	 	 	 	 	9B. DATED (SEE ITEM 11)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	þ 	 	10A. MODIFICATION OF CONTRACT/ ORDER 
    HHSO100200700032C
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	10B. DATED (SEE ITEM 13)	 	 	 	 
	CODE	 	 	 	 	 	FACILITY CODE	 	 	 	 	 	01-03-07	 	 	 	 
	 
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
 
	o The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers o is extended, o is not extended.
	 
	Offers must
acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning
              
copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR
ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE
RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN
REJECTION OF YOUR OFFER. If by virtue of this amendment, you
desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
	 
	12. ACCOUNTING AND
APPROPRIATION DATA (If required)
	SOCC:                      DOC#                      TIN#                      LOC#              
        CAN#                     
	 
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS; IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
	 
	 	 	A.	 	THIS CHANGE ORDER IS
ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	B.	 	THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT
 THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR

43.103(b).	 	

	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	þ 	 	C.	 	THIS SUPPLEMENTAL
AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

Far 1.602-1,
FAR 52-242-15 Stop-Work Order	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	D.	 	OTHER (Specify type of modification and authority)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	E. IMPORTANT: Contractor o is not, þ  is required to sign this document and return 2 copies to the issuing office.
	 
	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PURPOSE: The purpose of this modification is to:
	 
	 	 	1. Extend the period
of the Stop-Work Order issued January 4, 2008 an additional 90 days
from April 4, 2008  through July 3, 2008. 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	The total contract amount remains unchanged. ($102,661,429)
	 
	The contract completion date remains unchanged. (December 31, 2010)
	 
	Except as provided herein, all terms and conditions referenced in item 9A or 10A, as heretofore changed, remains full force and effect.
	 
	15A. NAME AND TITLE OF SIGNER (Type or print)	 	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 Michael Darwin	 	 	 	 	 	Schuyler T. Eldridge	 	 	 	 	 	 	 	 
	 
	15B. CONTRACTOR/OFFEROR	 	 	 	15C. DATE SIGNED	 	16B. UNITED STATES OF AMERICA	 	 	16C. DATE SIGNED
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	/s/ Michael Darwin	 	4/3/08 	 	BY  /s/ Schuyler T. Eldridge                        	 	 	 	4/3/08
	(Signature of person authorized to sign)	 	 	 	(Signature of Contracting Officer)	 	 	 	 	 	 	 	 	 	 
	 
	NSN
7540-01-152-8070	 	 	 	OMB No. 0990–0115	 	STANDARD FORM 30 (REV. 10-83)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]